Effects of Denosumab on Bone Microarchitecture After Total Knee Arthroplasty
NCT ID: NCT05559268
Last Updated: 2022-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
60 participants
INTERVENTIONAL
2022-10-01
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Efficacy of Denosumab in Decreasing Periprosthetic Bone Loss in Patients With Total Knee Arthroplasty
NCT02760979
Platelet Rich Plasma and Neural Prolotherapy Injections in Treating Knee Osteoarthritis
NCT04006314
High Frequency Intensive Autologous PRP Injection and Genicular Nerve Blocks in Treating Knee Osteoarthritis
NCT04088045
Altering Bone Microarchitecture and Mechanics by Off-label Pharmaceutical Intervention Following an Acute Knee Injury
NCT05204836
Intraosseous With Intra-articular Injection of Platelet Rich Plasma in Treatment of Knee Osteoarthritis
NCT03329235
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Denosumab
Denosumab 60 MG/ML Injectable Solution [Prolia]
1 ml (60 mg) subcutaneous injection Denosumab give in the posterior part of the upper arm after TKA
Placebo
Placebo
1 ml (60 mg) subcutaneous injection Saline give in the posterior part of the upper arm after TKA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Denosumab 60 MG/ML Injectable Solution [Prolia]
1 ml (60 mg) subcutaneous injection Denosumab give in the posterior part of the upper arm after TKA
Placebo
1 ml (60 mg) subcutaneous injection Saline give in the posterior part of the upper arm after TKA
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
50 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Affiliated Hospital of Qingdao University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiang Shuai, MD
Dr.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Denosumab AHQD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.